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Abstract. We previously reported that hepatic stellate cells 
(HSCs) activated by angiotensin II (AngII) facilitate stromal 
fibrosis and tumor progression in intrahepatic cholangiocarci-
noma (ICC). AngII has been known as a growth factor which 
can promote epithelial-to-mesenchymal transition (EMT) in 
renal epithelial cells, alveolar epithelial cells and peritoneal 
mesothelial cells. However, in the past, the relationship between 
AngII and stromal cell-derived factor-1 (SDF-1) in the micro-
environment around cancer and the role of AngII on EMT 
of cancer cells has not been reported in detail. SDF-1 and its 
specific receptor, CXCR4, are now receiving attention as a 
mechanism of cell progression and metastasis. In this study, we 
examined whether activated HSCs promote tumor fibrogenesis, 
tumor progression and distant metastasis by mediating EMT via 
the AngII/AngII type 1 receptor (AT-1) and the SDF-1/CXCR4 
axis. Two human ICC cell lines and a human HSC line, LI-90, 
express CXCR4. Significantly higher concentration of SDF-1α 
was released into the supernatant of LI-90 cells to which AngII 
had been added. SDF-1α increased the proliferative activity of 
HSCs and enhanced the activation of HSCs as a growth factor. 
Furthermore, addition of SDF-1α and AngII enhanced the 
increase of the migratory capability and vimentin expression, 
reduced E-cadherin expression, and translocated the expres-
sion of β-catenin into the nucleus and cytoplasm in ICC cells. 
Co-culture with HSCs also enhanced the migratory capability 
of ICC cells. These findings suggest that SDF-1α, released 
from activated HSCs and AngII, play important roles in cancer 
progression, tumor fibrogenesis, and migration in autocrine and 
paracrine fashion by mediating EMT. Our mechanistic findings 
may provide pivotal insights into the molecular mechanism of 
the AngII and SDF-1α-initiated signaling pathway that regulates 
fibrogenesis in cancerous stroma, tumor progression and meta-
stasis of tumor cells expressing AT-1 and CXCR4. 
Introduction
Intrahepatic cholangiocarcinoma (ICC) is highly fatal due to 
early invasion, rich fibrous stroma, and widespread metastasis. 
Current therapies for locally advanced or metastatic disease 
have little effect on the natural history of this malignancy. 
Understanding the molecular mechanisms underlying the 
progression of ICC may provide insights allowing the develop-
ment of novel anti-neoplastic therapies. Chemokines are major 
regulators of cell migration and adhesion especially in the bone 
marrow microenvironment and are involved in the trafficking of 
lymphocytes and leukocytes during inflammation and immune 
responses. Recently, some evidences have been obtained about a 
role of the chemokine stromal cell-derived factor-1 (SDF-1) and 
its specific receptor, CXCR4, in cell cycle progression, migra-
tory behavior, survival, and metastasis of tumor cells (1-4). 
Carcinoma-associated fibroblasts (CAFs) are thought to promote 
the growth of cancerous cells, angiogenesis, and stromal fibrosis 
by recruiting endothelial progenitor cells through the interaction 
between CXCR4 and SDF-1 released from CAFs (2,5). In our 
previous study, we demonstrated that hepatic stellate cell (HSC) 
activation by angiotensin II (AngII) facilitated stromal fibrosis 
and tumor progression via an interaction with cancer cells in 
ICC tissues (6). Tumor progression and fibrosis are pivotal 
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aspects of malignancy and several factors, including epidermal 
growth factor (EGF), transforming growth factor-β (TGF-β), 
hepatocyte growth factor (HGF), vascular endothelial growth 
factor (VEGF), trypsinogen, AngII, and chemokines including 
SDF-1, are regarded as possibly being involved in cross-talk in 
tumor-stromal interactions (2-8).
The epithelial-to-mesenchymal transition (EMT) is a process 
initially observed in embryonic development in which cells lose 
epithelial characteristics and gain mesenchymal properties 
such as increased motility and the capacity for invasion (9,10). 
Growth factors such as EGF, TGF-β, HGF and VEGF have 
been found to induce EMT (11-14). EMT is also a critical event 
that is occasionally observed during solid tumor progression, 
including invasion and metastasis, by which cancer cells acquire 
a more aggressive phenotype. Under these conditions, EMT is 
defined as the occurrence of a variable proportion of tumor 
cells up-regulating mesenchymal markers such as vimentin, 
and down-regulating epithelial markers such as E-cadherin 
and β-catenin (14,15). Expressions of these EMT markers are 
induced by growth factor/receptor systems such as the TGF-β/
TGF-β receptor system (12,16). However, little is known about 
EMT induced by cytokines and chemokines, including AngII 
and SDF-1, despite abundant evidence of their involvement in 
the diverse cancer cells. AngII has been known as a growth 
factor which can occur EMT in renal epithelial cells, peritoneal 
mesothelial cells and alveolar epithelial cells (17-19). But in the 
past, the relationship between AngII and SDF-1 in the micro-
environment around cancer tissues and the role of AngII on 
EMT of cancer cells has not been reported in detail.
We investigated whether HSCs activated by AngII in 
cancerous stromal tissues released SDF-1 into collagen-rich 
ICC tissues and hypothesized that the AngII/AngII type 1 
receptor (AT-1) axis and SDF-1/CXCR4 axis activate the fibro-
genesis in cancerous stroma, tumor invasion, and metastasis 
of ICC cells by mediating EMT via a synergistic interaction 
between cancer cells and CAFs including activated HSCs.
Materials and methods
Human tissue samples. The current study included 22 specimens 
of primary ICC (well to poorly-differentiated adenocarcinoma) 
that were surgically resected between 1998 and 2009. The 
average age of ICC patients was 64 years (range 35-84). The 
patients had stage I to IVB disease on the basis of the General 
Rules for the Clinical and Pathological Study of Primary Liver 
Cancer (20). Immediately following surgical removal, the tissue 
samples were frozen in liquid nitrogen and stored at -80˚C until 
the time of the assay for measuring AngII concentration. For 
immunohistochemical examination, the materials employed in 
this study, 20% formalin-fixed and paraffin-embedded speci-
mens, were retrieved from the surgical pathology files of the 
Pathology Section of Kanazawa University Hospital, Kanazawa, 
Japan.
Measurement of angiotensin II in tissues. The determination of 
AngII concentration in ICC tissue was performed as follows. 
Briefly, tissue samples were homogenized at 4˚C in saline 
containing 0.1 N HCl and 5% urinastatin. The homogenate was 
sedimented at 10000 x g for 30 min at 4˚C, and the supernatant 
was used for radioimmunoassay of AngII using the florisil 
method (florisil absorption and elution with acetone-hydro-
chloric acid solution) as described previously (21). This method 
is sensitive, specific and useful for routine clinical investigation. 
Parallel frozen tissue samples were homogenized in phosphate-
buffered saline (PBS).
Cell culture. Two human ICC cell lines [HuCCT-1, obtained 
from the Cell Resource Center for Biochemical Research, 
Tohoku University, Sendai, Japan (22) and CCKS-1, obtained 
from the Department of Human Pathology, Kanazawa University 
Graduate School of Medicine, Kanazawa, Japan (23)], and 
a human hepatic stellate cell line [LI-90, obtained from the 
Human Science Cell Bank, Saitama, Japan (24)] were used. 
ICC cell lines were maintained at 37˚C in a 5% CO2 incubator 
and grown in RPMI-1640 medium supplemented with 2 mM 
glutamine, 10% fetal bovine serum (FBS), 100 U/l penicillin 
and 100 µg/ml streptomycin. LI-90 cell lines were maintained at 
37˚C in a 5% CO2 incubator and grown in Dulbecco's modified 
Eagle's medium (DMEM) supplemented with 2 mM glutamine, 
10% FBS, 100 U/l penicillin and 100 µg/ml streptomycin.
Reagents and antibodies. AngII was used at concentrations of 
1, 10, 100 or 1000 nM. An active compound, telmisartan, which 
is a novel, long-acting, selective AT-1 receptor antagonist, was 
purchased from Sigma-Aldrich (St. Louis, MO, USA) and used 
at concentrations of 100 and 1000 nM, according to a previous 
report (6). Human recombinant SDF-1α was purchased from 
Sigma-Aldrich and was used at concentrations of 1, 10 or 100 ng/
ml according to a previous report (3). A CXCR4 antagonist, 
AMD3100 octahydrochloride hydrate, was purchased from 
Sigma-Aldrich and used at concentrations of 100 or 1000 ng/ml. 
TGF-β1 was purchased from Sigma-Aldrich and was used at a 
concentration of 10 ng/ml. For primary antibodies, we obtained 
goat polyclonal SDF-1 antibody (Santa Cruz Biotechnology, CA, 
USA), goat polyclonal CXCR4 antibody (Santa Cruz), mouse 
monoclonal α-smooth muscle actin (α-SMA) antibody (Sigma-
Aldrich), mouse monoclonal β-actin antibody (Sigma-Aldrich), 
rabbit polyclonal glial fibrillary acidic protein (GFAP) antibody 
(Dako Cytomation, Glostrup, Denmark), mouse monoclonal 
E-cadherin antibody (Zymed Laboratories, CA, USA), mouse 
monoclonal β-catenin antibody (Santa Cruz), and mouse mono-
clonal vimentin antibody (Santa Cruz).
Immunohistochemistry. The expressions of SDF-1 and CXCR4 
in resected ICC specimens were examined immunohisto-
chemically using each primary antibody by LSAB (labeled 
streptavidin-biotin) method. To identify the antigen in tissues, 
deparaffinized sections were pretreated by autoclaving in 
10% citric acid buffer (pH 8.0) at 120˚C for 15 min. After 
pretreatment with protein block serum (Dako Cytomation, 
Kyoto, Japan) for 10 min and in 2% skim milk for 20 min to 
block non-specific reactions, the sections were incubated with 
each primary antibody at 4˚C overnight. After incubation, the 
slides were incubated with biotinylated rabbit anti-goat IgG 
(Vector Laboratories, CA, USA) for 1 h at room temperature 
and then with LSAB solution (LSAB kit, Dako) for 1 h at room 
temperature. The reaction products were developed in 0.02% 
3,3'-diaminobenzidine tetrahydrochloride (DAB) solution 
containing 0.1% H2O2. To identify the antigens of α-SMA and 
GFAP in HSCs and E-cadherin, β-catenin and vimentin in 
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ICC cells, we examined using HRP (horseradish peroxidase) 
method. The Envision+ polymer solution (HRP-conjugated 
secondary antibody, Dako Cytomation) was then applied for 1 h 
after primary antibody treatment. The reaction products were 
developed in DAB solution containing 0.1% H2O2. The sections 
were then lightly counterstained with hematoxylin. The slides 
were examined under a fluorescence microscope (Olympus, 
Tokyo, Japan). Specimens were classified as positive when 
>10% of cancer cells were stained. The intensity of each type 
of staining was graded as negative (no stain or weak positive) 
and positive (intermediate or strongly positive) microscopically.
Immunocytochemistry. The suspensions of cancer cells were 
seeded onto a Lab-Tek Chamber Slide System (2-well) (Nalge 
Nunc International, Rochester, NY, USA) and incubated for 
24-48 h at 37˚C in a humid atmosphere of 5% CO2/95% air. The 
coverslips with cells were then fixed with methanol and acetone 
1:1 (v/v). After pretreatment with protein blocking serum for 
10 min to block non-specific binding, immunostaining for the 
expressions of CXCR4 in ICC cells was performed using the 
LSAB kit. Briefly, the slides were incubated with primary anti-
body (1:50) at 4˚C overnight. After washing, biotinylated rabbit 
anti-goat IgG was applied for 1 h and then LSAB solution for 
1 h at room temperature. The reaction products were visualized 
via a DAB reaction. The cells were then lightly counterstained 
with hematoxylin and examined under a fluorescence micro-
scope. 
Western blot analysis. Western blotting was performed as 
descrived previously (6). The polyvinylidene difluoride (PVDF) 
membrane were incubated for 2 h at room temperature with 
primary antibody against CXCR4 diluted 1:1000 with washing 
solution, followed by an HRP-conjugated anti-goat antibody 
diluted 1:5000 with washing solution. Chemiluminescence was 
detected with the ECL Plus Western Blotting Detection System 
(GE Healthcare Bioscience, Japan). We also used anti-SDF-1 
antibody for Western blotting to measure the up- or down-
regulation of SDF-1 expressions in LI-90 incubated in medium 
to which AngII (100 nM) or TGF-β1 (10 ng/ml) added.
Extraction of RNA and reverse transcriptase polymerase 
chain reaction (RT-PCR) for SDF-1, CXCR4 and GAPDH 
mRNA. After the isolation of mRNA using TRI Reagent 
(Sigma-Aldrich) and synthesize first-strand cDNA using 
RNeasy Mini Kit (Qiagen, USA) and QIA shredder (Qiagen), 
PCR for SDF-1, CXCR4 and GAPDH was performed with a 
TaqMan PCR Kit (Takara, Japan), according to the manu-
facturer's instructions. The SDF-1 forward primer sequence 
was 5'-CCGCGCTCTGCCTCAGCGACGGGAAG-3' and the 
reverse was 5'-CTTGTTTAAAGCTTTCTCCAGGTACT-3' 
(this pair generated a 227-bp fragment). The CXCR4 forward 
primer sequence was 5'-TTCTACCCCAATGACTTGTG-3' and 
the reverse was 5'-ATGTAGTAAGGCAGCCAACA-3' (this 
pair generated a 260-bp fragment). The GAPDH oligonucleotide 
primer set (forward 5'-ACCACAGTCCATGCCATCAC-3', 
reverse 5'-TCCACCACCCTGTTGCTGTA-3'; this pair gener-
ated a 452-bp fragment) was used as an internal standard. PCR 
was performed for 35 cycles (denaturation at 98˚C for 15 sec, 
annealing at 58˚C for 30 sec, and extension at 74˚C for 45 sec). 
After PCR, 5 µl samples of the products were subjected to 
2.0% agarose gel electrophoresis and stained with ethidium 
bromide. 
Enzyme-linked immunosorbent assay (ELISA) of SDF-1α. The 
baseline levels of SDF-1α production by LI-90 cells treated with 
and without different concentrations (0.1-100 ng/ml) of AngII 
were determined. LI-90 cells were seeded onto 6-cm dishes at a 
density of 1x105/ml and cultured for 24 h. Pretreatment with an 
antagonist of AngII, telmisartan (1000 nM), was carried out for 
30-60 min before the addition of AngII. After the medium had 
been replaced with fresh medium, the cells were cultured for 
another 48 h. The concentration of SDF-1α in the supernatant 
was measured by ELISA using a human SDF-1α antibody and 
an enzyme immunoassay kit (R&D Systems), according to the 
manufacturer's instructions. 
Cell proliferation assay. The proliferative effect of SDF-1α 
on HSCs was quantified using an MTT colorimetric assay 
with Cell Proliferation Kit I (Roche, Basel, Switzerland), as 
descrived previously (6). In brief, LI-90 cells (5x103 cells/well) 
was grown in 96-well flat-bottom microtiter plates in 100 µl of 
medium including 1% FBS and incubated for 48-96 h at 37˚C 
in a humidified atmosphere (e.g., 37˚C, 5% CO2). The medium 
contained different concentrations (0.1-100 ng/ml) of SDF-1α. 
In some experiments, AMD3100, an antagonist of CXCR4, was 
added to the SDF-1α treatment to assure that the proliferative 
effect caused by SDF-1α occurred via the CXCR4 receptor. 
After the incubation period, 10 µl of the MTT labeling reagent 
(final concentration 0.5 mg/ml) were added to each well, the 
microplate was incubated for 4 h in a humidified atmosphere 
(e.g., 37˚C, 5% CO2) and then 100 µl of the solubilization solu-
tion were added to each well. We allowed the plate to stand 
overnight in the incubator in a humidified atmosphere (e.g., 
37˚C, 5% CO2), then checked for complete solubilization of the 
purple formazan crystals, and measured the spectrophotometric 
absorbance value of the samples using a microplate reader. The 
wavelength for measuring absorbance of the formazan product 
is 595 nm. The experiments were repeated in triplicate wells. 
Cell viability was calculated as follows: Cell number (% of 
control) = (absorbance of experimental wells)/(absorbance of 
control wells) x 100 (%).
Fluorescent immunocytochemistry. LI-90 cells were grown on a 
Lab-Tek Chamber Slide System to 40%-60% confluence, serum-
deprived overnight (DMEM + 1% FBS), and then treated with 
100 ng/ml of SDF-1α or 10 ng/ml of TGF-β1 in the presence or 
absence of pretreatment for 1 h with 1000 ng/ml of AMD3100. 
CCKS-1 cells were seeded and grown on the Lab-Tek Chamber 
Slide System to 40%-50% confluence, serum-deprived over-
night (RPMI-1640 + 1% FBS), and then treated with or without 
100 ng/ml of SDF-1α in the presence or absence of pretreatment 
for 1 h with 1000 ng/ml of AMD3100. Cells were fixed with 
3.7% formalin for 10 min at room temperature. After washing 
the cells with PBS, non-specific binding was blocked with 
Protein Blocking Reagent (Dako) for 1 h at room temperature. 
LI-90 cells were incubated with the primary antibodies (α-SMA 
and GFAP) and ICC cells were incubated with each primary 
antibody (E-cadherin, β-catenin, or vimentin) overnight at 4˚C. 
Slides were then washed and incubated with the appropriate 
Alexa Fluor 488 and 592 nm phalloidin (Molecular Probes, Inc., 
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Eugene, OR, USA)-conjugated specific secondary antibodies 
for double staining for 1 h at room temperature. Cells were then 
incubated with Hoechst 33258 for nuclear staining for 5 min 
and mounted with propyl gallate containing phenylenediamine 
under glass coverslips. Cells were then visualized for immuno-
fluorescence with a laser scanning Olympus microscope at x10, 
x20 and x40 magnification or a Confocal LSM510 microscope 
(Carl Zeiss Microimaging, Inc., Thornwood, NY, USA) at x63 
magnification.
In vitro migration assays of cultured ICC cells. The migratory 
capabilities of both cultured ICC cell lines were assayed using 
a BD BioCoat Matrigel invasion chamber (24-well plate, 8-µm 
pore) (BD Biosciences, Bedford, MA, USA). Matrigel invasion 
chamber used in this study is a growth factor-reduced type. 
Medium (0.5 ml) containing 5x105 ICC cells was added to the 
upper chamber, and 0.5 ml of either medium alone or medium 
supplemented with 0.1, 1, 10 or 100 ng/ml of SDF-1α was added 
to the lower chamber. AMD3100 was used at 1000 ng/ml. For 
the migration assay of ICC cells co-cultured with LI-90 cells, 
medium (0.5 µl) containing 5x105 ICC cells was added to the 
upper chamber, and 0.5 ml of either medium alone or medium 
containing 4x104 LI-90 cells and 100 nM of AngII, 100 ng/ml of 
SDF-1α, or 10 ng/ml of TGF-β1 was added to the lower chamber 
with pretreatment of telmisartan or AMD3100. Chambers were 
incubated for 48 h at 37˚C and 5% CO2. ICC cells on the upper 
surface of the filter were removed using a cotton wool swab, and 
the cells that had migrated to the lower surface were stained 
using 1% toluidine blue after fixation with 100% methanol. The 
number of migratory cells was counted in 10 medium power 
fields (x20). Each experiment was conducted in triplicate. A 
migration index (the ratio of the number of migratory cells in 
an experimental group/the number of migratory cells in control 
groups with neither chemokines nor cytokines) was calculated 
in each experiment.
Figure 1. Correlation between AngII concentration and survival period. The 
dotted lines indicate the value of each AngII concentration of initial resected 
8 ICC tissues and their survival periods. Linear regression analysis showed a 
significant colleration between AngII concentration of resected ICC tissues 
and survival periods after resection.
Figure 2. Expression of CXCR4 and SDF-1 in ICC tissues. ICC cells are homogeneously positive for CXCR4 (A). Lymphoid cells in the surrounding liver are 
also positive for CXCR4. In addition, fibroblast-like stroma cells (arrows) are clearly positive for CXCR4 in cancerous stroma tissues. Original magnification, 
x200. Fibroblast-like stroma cells (arrows) are clearly positive for SDF-1 in ICC tissues (B). ICC cells are also weakly and homogeneously positive for SDF-1. 
Immunostaining for CXCR4 and SDF-1 counterstained by hematoxylin. Original magnification, x100. In immunocytochemistry for CXCR4 in ICC cells and 
HSCs, CXCR4 expression was intense in HuCCT-1 (C), CCKS-1 (D) and LI-90 cells (E). CXCR4 immunoreactivity was diffusely evident in membranous and 
granular cytoplasmic patterns. 
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Statistical analysis. Regression analysis was examineed for a 
correlation between AngII concentration in ICC tissues and 
survival periods. Statistical analyses were carried out using 
Student's unpaired t-test. Univariate analysis for survival was 
performed by using log-rank tests. P<0.05 was considered statis-
tically significant.
Results
Correlation between AngII concentration in ICC tissues and 
survival. The dotted lines indicate the value of each AngII 
concentration of initially resected 8 ICC tissues. There is a 
significant colleration between AngII concentration of resected 
ICC tissues and survival periods after resection. It is noteworthy 
that the higher concentration of AngII is, the longer the survival 
period of resected patient is. This result confirmed that the 
patients whose resected ICC tissues had higher AngII concen-
tration had significantly poorer prognosis compared with the 
patients having lower AngII concentration (Fig. 1). 
Expression of CXCR4 and SDF-1 in resected ICC specimens. 
Immunohistochemistry showed CXCR4 to be expressed in 12 of 
16 (75%) surgical specimens of human ICC. Immunoreactivity 
of CXCR4 was diffusely positive in the cytoplasm of cancer 
cells. In addition, fibroblast-like stromal cells were clearly posi-
tive for CXCR4 in the cancerous stroma (Fig. 2A, arrows). In 
the surrounding liver, hepatocytes were weakly positive and 
lymphoid cells were positive for CXCR4 as well. ICC cells 
were weakly and diffusely positive for SDF-1 and fibroblast-
like stromal cells were clearly positive for SDF-1 in cancerous 
stromal tissues (Fig. 2B, arrows). In the surrounding liver, a few 
fibroblasts, hepatocytes, and bile ducts were positive for SDF-1. 
CXCR4 and SDF-1 expressions in human ICC and HSC cells. 
Immunoreactivity of CXCR4 receptor was evident in membra-
nous and granular cytoplasmic patterns in HuCCT-1, CCKS-1 
and LI-90 cells (Fig. 2C-E). CXCR4 expression at the mRNA 
level was detected in all three cell lines by RT-PCR (208 bp, 
Fig. 3A). LI-90 cells expressed SDF-1 mRNA and protein 
constitutively, whereas no ICC cells in either cell line expressed 
SDF-1 mRNA (228 bp, Fig. 3A). Western blot analysis demon-
strated CXCR4 protein expression in all three cell lines (46 kDa, 
Fig. 3B).
SDF-1α released from activated HSCs induced cell prolif-
eration at autocrine fashion. LI-90 cells were incubated with 
100 nM AngII and 10 ng/ml TGF-β1. Western blotting showed 
that, SDF-1α protein was more clearly detectable in cultured 
LI-90 cells with 100 nM AngII or 10 ng/ml TGF-β1 treatment 
than in untreated cells (Fig. 4A). ELISA showed the SDF-1α 
level in the supernatant of untreated cultured LI-90 cells to be 
16.67±5.3 pg/ml. The addition of 1-1000 nM of AngII in the 
supernatant of the cultured LI-90 cells induced a dose-depen-
Figure 4. (A), Western blotting shows that SDF-1α protein in cultured LI-90 cells was weakly detected without treatment, but was clearly detected by incubating 
with 100 nM AngII or 10 ng/ml TGF-β1. (B), ELISA shows that SDF-1α protein level in the supernatant of the cultured LI-90 added 100 nM AngII significantly 
increased compared with untreated cells. The pretreatment with 1000 nM telmisartan in the supernatant of the cultured LI-90 added 100 nM AngII significantly 
inhibited the increase of SDF-1α protein level. Results are the means ± SD of triplicate experiments. *P<0.05 compared with control (untreated) cells by unpaired 
t-test.
Figure 3. (A), In RT-PCR, SDF-1 expression at the mRNA level was not detected 
in HuCCT-1 and CCKS-1 cells, but was detected in LI-90 cells. (B), Western blot 
analysis demonstrated CXCR4 protein expression in all three cells. GAPDH and 
β-actin were used as internal controls.
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dent increase in SDF-1α protein level. The addition of 100 nM 
AngII to the supernatant of cultured LI-90 cells induced a 
significant increase in SDF-1α as compared with untreated cells 
(31.82±5.3 pg/ml) and pretreatment with 1000 nM telmisartan 
significantly inhibited the increase in the release of SDF-1α 
protein (18.19±4.5 pg/ml) (Fig. 4B). These results indicated 
that SDF-1α released from LI-90 cells into the supernatant was 
down-regulated by antagonizing AT-1 receptor. To examine the 
proliferative effect of SDF-1α on HSCs, LI-90 cells were treated 
with SDF-1α and the proliferative effects were quantified by 
MTT assay. After a 48-h incubation, the proliferation of LI-90 
cells was dose-dependently increased by SDF-1α at concentra-
tions from 1 to 100 ng/ml. AMD3100 significantly inhibited the 
100 ng/ml SDF-1α-induced proliferative effect at a concentra-
tion of 1000 ng/ml (Fig. 5).
SDF-1α enhanced the activation of HSCs. GFAP is known to 
be expressed in quiescent or partially activated HSCs as a cell-
specific marker of HSCs and α-SMA is known as a cell-specific 
marker of activated HSCs and myofibroblasts (25). When the 
quiescent HSCs were stimulated by attractants, the transdif-
ferentiation of HSCs into myofibroblasts and the expression of 
α-SMA in the cytoplasm were enhanced. In untreated HSCs, 
GFAP expression was ubiquitous in the cytoplasm of nearly 
all cells, while only partial α-SMA expression was seen in the 
cytoplasm. Fluorescent immunocytochemistry showed that 
adding 100 ng/ml SDF-1α to LI-90 cells increased the number 
of α-SMA-positive LI-90 cells as compared with control cells 
(Fig. 6A and B). AMD3100 at 1000 ng/ml inhibited the activa-
Figure 6. Fluorescent immunocytochemistry of SDF-1α-induced activation of LI-90 cells (green, α-SMA; red, GFAP; blue, nuclei). When LI-90 cells were added 
to SDF-1α, the number of α-SMA-positive cells increased [(A), control cells; (B), 100 ng/ml SDF-1α-treated cells]. AMD3100 inhibited the activation of cells [(C), 
SDF-1α 100 ng/ml + AMD3100 1000 ng/ml]. Addition of 10 ng/ml TGF-β1 also increased the number of α-SMA-positive cells (D).
Figure 5. Proliferative effects of SDF-1α in HSCs. LI-90 cells treated with each 
concentration of SDF-1α (0.1-100 ng/ml) dose-dependently increased in number 
at concentrations of SDF-1α from 1 to 100 ng/ml. AMD3100 completely inhib-
ited the 100 ng/ml SDF-1α-induced proliferative response at a concentration 
of 1000 ng/ml. Results are the means ± SD of triplicate experiments. *P<0.05 
versus control. **P<0.05 versus 100 ng/ml SDF-1α.
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tion of LI-90 cells (Fig. 6C). Addition of 10 ng/ml TGF-β1 to 
LI-90 cells induced the activation and the transformation into 
myofibroblasts (Fig. 6D).
Co-culture with LI-90 cells and the addition of SDF-1α 
enhanced migration capability of cultured ICC cells. When 
ICC cells were treated with 100 ng/ml of SDF-1α in the lower 
chamber, the numbers of migrating HuCCT-1 and CCKS-1 
cells significantly increased by 1.79- and 1.4-fold, respectively, 
as compared with control cells (Fig. 7). In contrast, more ICC 
cells migrated when LI-90 cells were co-cultured in the lower 
chamber; the migration index was 1.9-fold in HuCCT-1 and 
1.7-fold in CCKS-1 as compared to the control. It is conceivable 
that LI-90 cells produce some factors promoting the migration 
of cultured ICC cells. When 1000 ng/ml of AMD3100 was 
added to the culture medium of both ICC cells co-cultured with 
LI-90 cells, migration of ICC cells was significantly suppressed 
to the control level (Fig. 8).
AngII and SDF-1α enhanced the expression of EMT markers. 
Fluorescent immunocytochemistry revealed the expression of 
the epithelial adhesion molecule E-cadherin to be decreased 
48 h after AngII or SDF-1α treatment as compared with 
untreated HuCCT-1 and CCKS-1 cells. Furthermore, nuclear 
expression of β-catenin was increased 48 h after treatment with 
AngII or SDF-1α under serum-starved conditions. Pretreatment 
of ICC cells with telmisartan or AMD3100 inhibited the 
decrease in E-cadherin expression, while β-catenin expression 
in the nucleus was decreased (green, E-cadherin; red, β-catenin; 
Fig. 9A). Conversely, an increase in the expression of the mesen-
chymal cell marker vimentin was observed at 48 h after AngII 
or SDF-1α treatment. Furthermore, the increase in vimentin 
expression was also inhibited by adding 1000 nM telmisartan 
or 1000 ng/ml AMD3100 to ICC cells treated with AngII or 
SDF-1α (green, vimentin; blue, nucreus; Fig. 9B). 
Correlation between the expression of each markers and the 
prognosis. The patients were visually divided into two groups 
by the intensity of each type of staining in immunohistochem-
istry. The correlations between the degree of the expression of 
each markers and the clinicopathological features with median 
survival time (MST) are shown in Table I. There was no signifi-
cant difference on MST in the expression of β-catenin (P=0.059), 
CXCR4 (P=0.429), and the stage of resected ICC patients 
(P=0.116). Significant differences on MST were observed in 
the expression of E-cadherin, vimentin, SDF-1, and histo-
logical differentiated type. Negative expression of E-cadherin 
(P=0.007), positive expression of vimentin (P=0.011) and SDF-1 
(P=0.035), and poorly-differentiated type were found to have 
significantly poorer prognosis (P=0.044).
Discussion
In this study, we found that SDF-1, released from activated 
HSCs and AngII, contributes to stromal fibrosis, migration of 
cancer cells, and tumor progression in ICC tissues via EMT. It 
was suggested that AngII was associated with the synergistic 
effects on tumor fibrogenesis and tumor progression via SDF-1/
CXCR4 axis. Proliferation and activation of HSCs are the 
Figure 8. Migration of cultured ICC cells added with 100 nM AngII increased 
in co-culture with LI-90 cells in the lower chamber for 48 h (migration of 
HuCCT-1 cells increased from 1.41- to 1.94-fold and that of CCKS-1 increased 
from 1.23- to 1.69-fold, respectively, compared with the control). The increase 
of migration capability of both ICC cells co-cultured with LI-90 cells signifi-
cantly inhibited to the control level when 1000 nM telmisartan was added. 
Migration of cultured ICC cells with added 100 ng/ml SDF-1α increased  in co-
culture with LI-90 cells in the lower chamber for 48 h (migration of HuCCT-1 
cells increased from 1.53- to 2.04-fold and that of CCKS-1 increased from 
1.31- to 1.65-fold, respectively, compared with the control). The increase of 
migration capability of both ICC cells co-cultured with LI-90 cells signifi-
cantly inhibited to the control level when 1000 ng/ml of AMD3100 was added 
to the culture medium. Migration of cultured ICC cells with added 10 ng/ml 
TGF-β1 also increased in co-culture (migration of HuCCT-1 cells increased 
from 1.77- to 2.95-fold and that of CCKS-1 increased from 1.62- to 2.23-fold, 
respectively, compared with the control). *P<0.05 versus control cells. **P<0.05 
with versus without co-culture with LI-90 cells.
Figure 7. Migration of cultured ICC cells, increased when 0.1-100 ng/ml 
SDF-1α was added in the lower chamber (migration index of HuCCT-1 is 
1.07-, 1.21-, 1.42-, 1.79-fold, respectively, compared with the control. Migration 
index of CCKS-1 is 1.05-, 1.15-, 1.23-, 1.4-fold, respectively, compared with 
the control). Migration capability of HuCCT-1 and CCKS-1 cells significantly 
increased when 10 and 100 ng/ml of SDF-1α was added and the increase was 
inhibited when 1000 ng/ml AMD3100 was added to both cell lines. *P<0.05 
versus control. **P<0.05 versus 100 ng/ml SDF-1α. The number of migrated 
cells was counted in 10 medium power fields (x20). The data are provided as 
the mean ± SD. Migration assay was performed three times in each experiment. 
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dominant events in liver injury, inflammation and fibrosis that 
render cells responsive to cytokines and other local stimuli 
(25,26). The current study demonstrated the enhancement of 
SDF-1 secretion from activated HSCs stimulated by AngII and 
the role of SDF-1 on the proliferation and activation of HSCs. 
Our previous report showed ICC tissues to have higher AngII 
concentrations than hepatocellular carcinoma and normal liver 
tissues, and we described the role of the AngII/AT-1 axis in 
cancer proliferation and cancerous fibrogenesis via the activa-
tion of HSCs (6). Furthermore, it was previously reported that 
HSCs may contribute to the desmoplastic reaction, invasiveness, 
and cell proliferation associated with primary and metastatic 
liver tumors (8,27). It has also been reported that bone marrow-
derived fibroblasts contribute to tumor stromal reactions and 
tissue fibrosis and were recruited into cancer-induced stroma in 
late tumor stages (28). In terms of the role of chemokines on 
cancer cell proliferation, Ohira et al and Leelawat et al previ-
ously demonstrated that SDF-1 had no effect on the proliferative 
activity of cultured ICC cells (3,29). We also examined the 
proliferative effect of SDF-1α on HuCCT-1 and CCKS-1 cells by 
MTT assay, and our result was almost identical to their results 
(data not shown). On the other hand, we previously reported that 
AngII had a significantly proliferative effect on ICC cells and 
AngII receptor blocker, telmisartan, treatment had a suppressive 
effect on cell proliferation (6).
EMT, in which tumor cells undergo loss of polarity and cell-
cell junctions and acquire a mesenchymal phenotype and the 
capabilities of invading the extracellular matrix and migrating 
to distant sites, has been a research focus with local invasion and 
Table I. Correlation between the clinicopathological features and 
the expression of each markers with the prognosis of resected 
ICC patients.a
  No. MST P-value
   (month)
E-cadherin Positive 11 40 0.007
 Negative 11   9
β-catenin Membranous   9 24 0.059
 Cytoplasmic or 13 19
 intranuclear
Vimentin Positive 10 17 0.011
 Negative 12 40
SDF-1 Positive   6 21 0.035
 Negative 10 40
CXCR4 Positive   6 24 0.429
 Negative 10 21
Histological type well-mod 16 30 0.044
 por   6   9
Stage I-III 10 30 0.116
 IV 12 10
aNegative expression of E-cadherin, positive expression of vimentin 
and SDF-1, and histologically poorly-differentiated type were found 
to have significantly poorer prognosis.
Figure 9. Fluorescent immunocytochemistry of AngII- or SDF-1α-induced changes in mesenchymal markers of ICC cells. Addition of AngII or SDF-1α to ICC 
cells was found to disorganize, diffuse distribution in the cytoplasm, and down-regulate E-cadherin expression, whereas β-catenin translocated to the nucleus 
[(A): green, E-cadherin; red, β-catenin; blue, nuclei] and up-regulate vimentin [(B): green, vimentin; blue, nuclei]. Telmisartan inhibited the down-regulation of 
E-cadherin, translocation of β-catenin to the nucleus, and vimentin up-regulation in ICC cells treated with AngII. AMD3100 also inhibited the down-regulation 
of E-cadherin, translocation of β-catenin to the nucleus, and vimentin up-regulation in ICC cells treated with SDF-1α. 
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metastasis being of particular interest (30,31). Epithelial cancer 
cells have been known to transform to the cells with mesen-
chymal characteristics via stimulation with several cytokines or 
chemokines such as TGF-β1, VEGF, HGF and SDF-1 (9-14). In 
the current study, we obtained ample evidence that CXCR4 
activation by SDF-1 and AT-1 activation by AngII contribute 
to tumor progression by acting as a crucial mediator of EMT 
in vitro. We demonstrated that AngII and SDF-1 induced 
key events including down-regulation of epithelial adherens, 
such as E-cadherin and β-catenin, induction of mesenchymal 
marker, vimentin, and enhanced cell invasiveness and migra-
tion. Evidence of EMT in clinical tumor specimens has been 
established including loss or delocalization of junctional 
E-cadherin, switching to other cadherins (e.g., N-cadherin 
replaces E-cadherin), degradation of cell-to-cell adhesion, 
apicobasal polarity and tissue architecture alterations, pleio-
tropic cell shape, nuclear β-catenin, Snail or Slug expression, 
and the otherwise unexpected expressions of mesenchymal 
markers such as the intermediate filament protein vimentin 
(9,32,33). But in the past, no evidence has been reported on 
the pivotal correlation between AngII in the cancer tissues 
and EMT of cancer cells.
AngII shares many cellular responses with TGF-β. In the 
kidney, ling, liver and vascular, AngII actively participates 
in renal fibrosis and in the parts mediated by TGF-β. Many 
studies have shown that AngII inhibitors diminish renal 
TGF-β overproduction and signaling activation (26,34-41). 
A recent study found that AngII directly activates the Smad 
signaling system via AT-1 receptor in the kidney and induces 
the up-regulation of growth factors, extracellular matrix 
accumulation and EMT through the TGF-β/Smad pathway 
(36,37). The AT-1 signaling mechanisms are similar to those 
activated by cytokines, and include activation of protein 
kinases, e.g., the mitogen-activated protein kinase (MAPK) 
cascade and Rho-kinase (ROCK). Recent studies have demon-
strated that the MAPK pathway regulates EMT via TGF-β 
(34,35). Previous investigations have shown that elucidating 
the molecular mechanisms involved in organ fibrosis might 
lead to improvements in current clinical treatments for fibrous 
diseases. Several studies have shown the MAPK pathway to 
be involved in EMT and fibrosis. AngII activates MAPK 
and through this pathway elicits many cellular responses. 
The specific inhibitors of all three MAPKs (p38, JNK and 
ERK1/2) prevented phenotypic conversion of cultured human 
epithelial cells into myofibroblasts and the loss of E-cadherin 
observed after 3 days of treatment with AngII, and markedly 
diminished inductions of the EMT markers vimentin and 
α-SMA. The MAPK pathway is involved in EMT, fibrosis 
and cell migration caused by TGF-β (34-41). 
CXCR4 is widely expressed on hematopoietic, brain, lung, 
colon, heart, kidney and liver cells. CXCR4 has been suggested 
to contribute to the metastatic homing of cancer cells to various 
organs and tissues and seems to be an important pro-invasive 
factor. Cells expressing functional CXCR4 have been suggested 
to migrate and/or invade along SDF-1 gradients (1,2). Previous 
reports demonstrated the role of CXCR4 signaling in local 
invasion and distant metastasis of breast cancer (42). SDF-1 is 
constitutively expressed in several organs including the lungs, 
liver, skeletal muscle, brain, kidneys, heart, skin and bone 
marrow and plays a role in the mobilization and recruitment of 
cells expressing CXCR4 to neoangiogenic niches supporting 
revascularization of ischemic tissue and tumor growth. 
Expression of CXCR4 on tumor cells, including those from 
several hemato poietic malignancies, implies that the SDF-1/
CXCR4 pathway may influence cancer biology and play an 
important role in directing the metastasis of tumor cells 
expressing CXCR4 to organs that express SDF-1 such as 
the lung, liver, bone or lymph nodes (1,2,42,43). Interactions 
between CAFs including activated HSCs and cancer cells 
expressing CXCR4 may induce tumor progression, cancer 
fibrogenesis, tumor invasion, and cancer metastasis via EMT 
(44,45), and may synergistically make ICC more highly 
malignant and more resistant to various therapies. The results 
shown in Table I are thought to be reasonable to support a 
correlation between the expression of SDF-1 and each EMT 
markers with the prognosis of ICC patients.
In conclusion, our results suggest that SDF-1 released from 
activated HSCs and AngII itself can contribute to stromal 
fibrosis and migration of cancer cells in collagen-rich liver 
tumors, such as ICC. A better understanding of the interplay 
between ICC cells and cancerous stroma will be important 
for developing strategies to improve tumor therapy that take 
into account the influences of the neoplastic microenviron-
ment on tumor fibrosis, survival, and growth. Additionally, 
AngII receptor blockers and CXCR4 antagonists may be 
useful for treating collagen-rich tumors. Targeting the SDF-1 
and AngII signaling pathways may be both a pivotal and an 
efficient strategy for treating high-grade neoplasms rich in 
cancerous stroma. 
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